British Journal of Cancer - Table of Contents alert Volume 106 Issue 12

TABLE OF CONTENTS Volume 106, Issue 12 (1901-2044) Published online 5 June 2012 In this issue Minireview Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics and Genomics Indexes Also new today Advance online publication Advertisement There's more to angiogenesis than just VEGF-A. Other factors in the VEGF family are also important in angiogenic processes like tumour vascularisation, vessel assembly, maturation and identity. Look beyong single-factor anti-angiogenesis - click here. For references see the anti-angiogenesis section of our website. Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Hot off the press!! Did you know this article from British Journal of Cancer recently appeared in the press? Use of Aspirin postdiagnosis improves survival for colon cancer patients E Bastiaannet, K Sampieri et al. Read this Article now!   Minireview Top The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression J M Houthuijzen, L G M Daenen, J M L Roodhart and E E Voest Br J Cancer 2012 106: 1901-1906; advance online publication, May 17, 2012; 10.1038/bjc.2012.201 Abstract | Full Text Clinical Studies Top Do the British public recognise differences in survival between three common cancers? K L Whitaker, A E Simon, R J Beeken and J Wardle Br J Cancer 2012 106: 1907-1909; advance online publication, May 3, 2012; 10.1038/bjc.2012.185 Abstract | Full Text Histological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening E O Fourkala, A Gentry-Maharaj, M Burnell, A Ryan, R Manchanda, A Dawnay, I Jacobs, M Widschwendter and U Menon Br J Cancer 2012 106: 1910-1916; advance online publication, May 17, 2012; 10.1038/bjc.2012.155 Abstract | Full Text Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer N Androulakis, S Agelaki, M Perraki, S Apostolaki, V Bozionelou, A Pallis, K Kalbakis, A Xyrafas, D Mavroudis and V Georgoulias Br J Cancer 2012 106: 1917-1925; 10.1038/bjc.2012.202 Abstract | Full Text Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases S De Bruyne, N Van Damme, P Smeets, L Ferdinande, W Ceelen, J Mertens, C Van de Wiele, R Troisi, L Libbrecht, S Laurent, K Geboes and M Peeters Br J Cancer 2012 106: 1926-1933; advance online publication, May 17, 2012; 10.1038/bjc.2012.184 Abstract | Full Text A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study Y Nakai, H Isayama, T Sasaki, N Sasahira, T Tsujino, N Toda, H Kogure, S Matsubara, Y Ito, O Togawa, T Arizumi, K Hirano, M Tada, M Omata and K Koike Br J Cancer 2012 106: 1934-1939; advance online publication, May 3, 2012; 10.1038/bjc.2012.183 Abstract | Full Text The risk of pancreatic cancer in symptomatic patients in primary care: a large case–control study using electronic records S Stapley, T J Peters, R D Neal, P W Rose, F M Walter and W Hamilton Br J Cancer 2012 106: 1940-1944; advance online publication, May 22, 2012; 10.1038/bjc.2012.190 Abstract | Full Text Translational Therapeutics Top Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model Y Kususda, H Miyake, M E Gleave and M Fujisawa Br J Cancer 2012 106: 1945-1952; advance online publication, May 15, 2012; 10.1038/bjc.2012.209 Abstract | Full Text γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer H Mizugaki, J Sakakibara-Konishi, Y Ikezawa, J Kikuchi, E Kikuchi, S Oizumi, T P Dang and M Nishimura Br J Cancer 2012 106: 1953-1959; advance online publication, May 17, 2012; 10.1038/bjc.2012.178 Abstract | Full Text False-negative MRI biomarkers of tumour response to targeted cancer therapeutics J K R Boult, Y Jamin, V Jacobs, L D Gilmour, S Walker-Samuel, J Halliday, P Elvin, A J Ryan, J C Waterton and S P Robinson Br J Cancer 2012 106: 1960-1966; advance online publication, May 17, 2012; 10.1038/bjc.2012.208 Abstract | Full Text In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival E Bicaku, Y Xiong, D C Marchion, H S Chon, X B Stickles, N Chen, P L Judson, A Hakam, J Gonzalez-Bosquet, R M Wenham, S M Apte, W Fulp, C L Cubitt, D-T Chen and J M Lancaster Br J Cancer 2012 106: 1967-1975; advance online publication, May 17, 2012; 10.1038/bjc.2012.207 Abstract | Full Text Molecular Diagnostics Top A novel oncogenic pathway by TLS–CHOP involving repression of MDA-7/IL-24 expression K Oikawa, M Tanaka, S Itoh, M Takanashi, T Ozaki, Y Muragaki and M Kuroda Br J Cancer 2012 106: 1976-1979; advance online publication, May 15, 2012; 10.1038/bjc.2012.199 Abstract | Full Text c-Myc and EBV–LMP1: two opposing regulators of the HLA class I antigen presentation machinery in epithelial cells C S Tudor, C W Dawson, J Eckhardt, G Niedobitek, A C Büttner, B Seliger, A Hartmann and M Buettner Br J Cancer 2012 106: 1980-1988; advance online publication, May 15, 2012; 10.1038/bjc.2012.197 Abstract | Full Text FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer Y Cimino, A Costes, D Damotte, P Validire, S Mistou, N Cagnard, M Alifano, J-F Régnard, G Chiocchia, C Sautès-Fridman and L Tourneur Br J Cancer 2012 106: 1989-1996; 10.1038/bjc.2012.196 Abstract | Full Text Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma S Hagiwara, M Kudo, T Nagai, T Inoue, K Ueshima, N Nishida, T Watanabe and T Sakurai Br J Cancer 2012 106: 1997-2003; advance online publication, May 17, 2012; 10.1038/bjc.2012.145 Abstract | Full Text Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients A S Felix, R P Edwards, R A Stone, M Chivukula, A V Parwani, R Bowser, F Linkov and J L Weissfeld Br J Cancer 2012 106: 2004-2009; advance online publication, May 22, 2012; 10.1038/bjc.2012.200 Abstract | Full Text The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer C H Richards, K M Flegg, C SD Roxburgh, J J Going, Z Mohammed, P G Horgan and D C McMillan Br J Cancer 2012 106: 2010-2015; advance online publication, May 17, 2012; 10.1038/bjc.2012.211 Abstract | Full Text Genetics and Genomics Top Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study A Jakubowska, D Rozkrut, A Antoniou, U Hamann, R J Scott, L McGuffog, S Healy, O M Sinilnikova, G Rennert, F Lejbkowicz, A Flugelman, I L Andrulis, G Glendon, H Ozcelik, OCGN13, M Thomassen, M Paligo, P Aretini, SWE-BRCA, J Kantala, B Aroer, A von Wachenfeldt, A Liljegren, N Loman, K Herbst, U Kristoffersson, R Rosenquist, P Karlsson, M Stenmark-Askmalm, B Melin, K L Nathanson, S M Domchek, T Byrski, T Huzarski, J Gronwald, J Menkiszak, C Cybulski, P Serrano, A Osorio, T R Cajal, M Tsitlaidou, J Benítez, M Gilbert, HEBON, M Rookus, C M Aalfs, I Kluijt, J L Boessenkool-Pape, H E J Meijers-Heijboer, J C Oosterwijk, C J van Asperen, M J Blok, M R Nelen, A M W van den Ouweland, C Seynaeve, R B van der Luijt, P Devilee, EMBRACE, D F Easton, S Peock, D Frost, R Platte, S D Ellis, E Fineberg, D G Evans, F Lalloo, R Eeles, C Jacobs, J Adlard, R Davidson, D Eccles, T Cole, J Cook, A Godwin, B Bove, GEMO Study Collaborators52, D Stoppa-Lyonnet, V Caux-Moncoutier, M Belotti, C Tirapo, S Mazoyer, L Barjhoux, N Boutry-Kryza, P Pujol, I Coupier, J-P Peyrat, P Vennin, D Muller, J-P Fricker, L Venat-Bouvet, O Th Johannsson, C Isaacs, R Schmutzler, B Wappenschmidt, A Meindl, N Arnold, R Varon-Mateeva, D Niederacher, C Sutter, H Deissler, S Preisler-Adams, J Simard, P Soucy, F Durocher, G Chenevix-Trench, J Beesley, X Chen, KConFab75, T Rebbeck, F Couch, X Wang, N Lindor, Z Fredericksen, V S Pankratz, P Peterlongo, B Bonanni, S Fortuzzi, B Peissel, C Szabo, P L Mai, J T Loud and J Lubinski on behalf of CIMBA, the Consortium of Investigators of Modifiers of BRCA1/2-Related Cancer Br J Cancer 2012 106: 2016-2024; advance online publication, May 15, 2012; 10.1038/bjc.2012.160 Abstract | Full Text Indexes Top Author Index for Volume 106 Br J Cancer 2012 106: 2025-2034; 10.1038/bjc.2012.247 Full Text Keyword Index for Volume 106 Br J Cancer 2012 106: 2035-2038; 10.1038/bjc.2012.248 Full Text Referee Acknowledgement for 2011 Br J Cancer 2012 106: 2039-2044; 10.1038/bjc.2012.249 Full Text Advertisement Ensure your access to British Journal of Cancer If you are unable to access the articles in this Table of Contents e-alert, your library may not subscribe to this journal. Our online recommendation form is a simple way to make your librarian aware that this journal is valuable to your research. Recommend now at http://www.nature.com/librec/svc/request/makeCommRequest?id=2.   Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.